Logo

Shanghai Public Health Clinical Center Initiated Functional Cure Study Evaluating ASC22 + Chidamide for Patients with HIV

Share this

Shanghai Public Health Clinical Center Initiated Functional Cure Study Evaluating ASC22 + Chidamide for Patients with HIV

Shots:

  • The study evaluates ASC22 (envafolimab, 1 mg/kg, SC, q4w) + Chidamide (10mg, q2w) for 12wks. in patients infected by human immunodeficiency virus (HIV) with antiviral suppression
  • The objective of the study is to evaluate the efficacy of dual regimen on the viral reservoirs of latently infected cells in HIV patients
  • ASC22 (SC) is a single domain Ab against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection like HBV and HIV

 Ref: PR Newswire | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions